Oppenheimer raised the firm’s price target on Tarsus Pharmaceuticals (TARS) to $65 from $63 and keeps an Outperform rating on the shares.

Revenue exceeded analyst estimates by 2.7%. Earnings per share (EPS) missed analyst estimates significantly. Looking ahead, ...

Reports Q3 revenue $148.3M, consensus $144.35M ... Try Now>> See today’s best-performing stocks on TipRanks >> Read More on ANIP: Biosante Pharmaceuticals NewsMORE Related Stocks Indices Commodities ...

The Company's full financial statements and related MD&A for the first quarter ended September 30, 2024, are available at www.inmedpharma.com, www.sedar.com and at www.sec.gov.

Revenue exceeded analyst estimates by 32%. Earnings per share (EPS) also surpassed analyst estimates significantly. Looking ahead, revenue is forecast to grow 13% p.a. on average during the next 3 ...

The United States Agency for International Development has announced a $2.3m commitment to procure 4.8 million doses of ...

The U.S. Agency for International Development (USAID) has committed $2.3 million to procure 4.8 million doses of life-saving ...

Bruce, Professional Relations Associate, 3M Pharmaceuticals, personal communication, March 2007). Of interest to us were the four subjects (15%) with reactions to fragrance mix. The positive ...

Merck-Sharp and Dohme), screening for HPV (Digene Corp.), and HPV therapy (3M Pharmaceuticals). Eduardo Franco has served as an occasional paid consultant to pharmaceutical and biotechnology ...

Community Health Network is suing insurer Humana Inc., claiming the Louisville company owes it $7.4 million in drugs for its ...

Stocks including Sagility India, Hindalco Industries, Britannia, ONGC, L&T Technology Services, Bank of India, NMDC, Awfis ...